Progyny Q2 FY26 earnings call PGNY

Progyny reported a strong second quarter with record revenue, gross profit, and adjusted EBITDA. The company achieved gross margin expansion of 180 basis points year-over-year and continued to generate significant operating cash flow, exceeding its 75% conversion target. This robust financial performance provides the flexibility to invest in platform expansion for future growth while also returning value to shareholders through ongoing share repurchases.

The current sales season is progressing favorably, with early commitments for new sales pacing meaningfully ahead of last year. This strong momentum, coupled with high client retention, positions Progyny to meet its annual target of adding 1 million or more new lives. New client acquisitions are diverse, spanning various industries like energy, manufacturing, healthcare, and financial services, and include clients of all sizes, from 1,000 covered lives to large enterprises.

Progyny has largely de-risked client turnover for 2027, with the vast majority of retention risk removed earlier than usual. Existing clients, having directly experienced the cost control and savings delivered by Progyny's solutions, are not only renewing but also expanding their services beyond core fertility, taking business from competitors. New clients are also selecting typical levels of coverage, indicating sustained demand for comprehensive benefits.

Family building and women's health solutions remain a high priority for employers, especially as they face escalating medical and pharmacy cost trends, often exceeding 10%. Employers are increasingly seeking solutions with a proven track record of cost control, quality management, and high member satisfaction. Progyny believes its transparent reporting and consistent delivery across these criteria uniquely position it to win in a competitive market.

Progyny is advancing several strategic initiatives, including health plan partnerships, public sector client engagement, and the development of Progyny Select for the fully insured market. Existing health plan partnerships are showing good results and increased productivity. While Progyny Select is not expected to be a meaningful contributor in 2027, it is viewed as an important long-term growth driver, with current efforts focused on building relationships with key distribution partners.

The company anticipates a slightly more pronounced seasonal impact in Q3, particularly during the summer months, which has led to a recalibration and narrowing of its full-year guidance. However, management views this as an ordinary seasonal rhythm, not a new macro trend, and expects member engagement to return to normal levels in September, maintaining consistency with long-established historical ranges for the full year.

Progyny's disciplined capital management has resulted in a high conversion of adjusted EBITDA to operating cash flow, enabling significant shareholder returns. The company has purchased 10.8 million shares overall since November, reducing its total shares outstanding by approximately 12.5%. A new $200 million share repurchase authorization was announced in May, under which nearly 1.2 million shares were bought in Q2.